Rare Event Analysis in Flow Cytometry: Design Control and Validation Aligned with CLSI H62, Upcoming Webinar Hosted by Xtalks

TORONTO, March 15, 2023 /PRNewswire-PRWeb/ -- Rare event analysis by flow cytometry is relatively common in research settings, in clinical laboratories and during drug discovery and development. For example, in research and drug discovery environments, the measurement of intracellular cytokines and intracellular signaling events (i.e., protein phosphorylation) are some of the more common rare event assays. Whereas in clinical laboratories, assays for rare events often include the measurement of CD34+ hematopoietic stem cells, paroxysmal nocturnal hemoglobinuria (PNH) and minimal residual disease (MRD) of blood cancers. During drug development and clinical trial evaluation of new therapeutic modalities, rare event methods might also include the monitoring of CAR cellular therapies and the efficacy of cell-depleting therapies.